Abstracts Archive - Page 2051 of 2425 - ACR Meeting Abstracts

Abstract Number: 13 • 2014 ACR/ARHP Annual Meeting
Eculizumab in Antiphospholipid Antibody Syndrome
Ekaterini Zapantis¹, Richard Furie² and Diane Horowitz¹, ¹Rheumatology, North Shore - Long Island Jewish Health System, Great Neck, NY, ²Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY
Background/Purpose Antiphospholipid syndrome (APS) is defined as the occurrence of venous or arterial thrombosis and/or pregnancy morbidity, in the presence of serological evidence of antiphospholipid…
Abstract Number: 12 • 2014 ACR/ARHP Annual Meeting
Non-Criteria Antiphospholipid Antibodies in Obstetrical “seronegative Anti-Phospholipid syndrome”
Arsene Mekinian¹, Marie Charlotte Bourrienne², Lionel Carbillon³, Sabine Grootenboer², Luc Dechaisemartin⁴, Sylvie chollet Martin², Olivier Fain⁵ and Pascale Nicaise-Roland⁶, ¹Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³Service de gynécologie-obstétrique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, ⁴Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, PARIS, France, ⁵Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁶Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, Paris, France
Background/Purpose The aims of our prospective study were to determine the prevalence of non-criteria aPL and their clinical relevance in a seronegative population with pregnancy…
Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Mileka Gilbert¹ and Lenore M. Buckley², ¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ²Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
Abstract Number: 9 • 2014 ACR/ARHP Annual Meeting
A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation
Vinicius Domingues¹, Darshana Dadhania², Choli Hartono², Raymond Pastore³ and Doruk Erkan⁴, ¹1320 York Avenue 17n, New York Presbyterian Hospital, New York, NY, ²Nephrology and Hypertension, New York Presbyterian Hospital, new york, NY, ³Hematology and Oncology, New York Presbyterian Hospital, new york, NY, ⁴Rheumatology, Hospital for Special Surgery; Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Antiphospholipid antibody (aPL) positive patients undergoing kidney transplantation (Tx) are at increased risk for perioperative complications. The objective of this study was to analyze…
Abstract Number: 8 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
Nicolas Noel¹, Fabien Dutasta², Nathalie Costedoat-Chalumeau³, Boris Bienvenu⁴, Xavier Mariette⁵, Loik Geffray⁶, Damien Sène⁷, Jean-Marie Michot¹, Olivier Fain⁸, Luc Darnige⁹, Annick Ankri¹⁰, Patrice Cacoub¹¹, Jean-Charles Piette¹¹ and David Saadoun¹¹, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Hôpital d'Instruction des Armées Percy, Service de Médecine Interne, Clamart, France, ³Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ⁶CH Lisieux, Service de Médecine Interne, Lisieux, France, ⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ⁸Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁹Hôpital Européen Georges Pompidou, service d'hématologie biologique, Paris, France, ¹⁰Groupe Hospitalier Pitié Salpétrière, service d'hématologie biologique, Paris, France, ¹¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose Long term anticoagulation is recommended in antiphospholipid syndrome with thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K antagonists,…
Abstract Number: 7 • 2014 ACR/ARHP Annual Meeting
Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Ángeles Aguirre Zamorano¹, Nuria Barbarroja¹, Patricia Ruiz-Limon¹, Yolanda Jiménez Gómez¹, Munther A. Khamashta², Antonio Rodriguez-Ariza³, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁵, Eduardo Collantes-Estevez¹ and Mª Jose Cuadrado⁶, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Cell Biology, Physiology, and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁵Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁶Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose To investigate the beneficial effects of in vivoubiquinol (Q) supplementation on athero-thrombosis prevention in APS patients. Methods The study was performed on 10 APS…
Abstract Number: 6 • 2014 ACR/ARHP Annual Meeting
Performance Evaluation and Clinical Associations of the Aphl ELISA Compared to Criteria Antiphospholipid Immunoassays in Lupus Patients
Yu Zuo^1,2, Rohan Willis³, Emilio Gonzalez⁴, Allan Brasier⁵, Michelle Petri⁶, Elizabeth Papalardo⁷, E Nigel Harris⁸, Hong Fang⁹, Karel De Ceulaer¹⁰, Monica Smikle¹¹, Luis M. Vila¹², John D. Reveille^13,14, Graciela S. Alarcon¹⁵ and Silvia Pierangeli¹⁶, ¹Internal Medicine, University of Texas Medical Branch in Galveston TX, Galveston, TX, ²Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³515 1st St. Apt. 360, UTMB - Galveston, Galveston, TX, ⁴Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁵Internal Medicine, Endocrinology, UTMB-Galveston, Galveston, TX, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Louisville APL Diagnostic, seabrook, TX, ⁸Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica, ⁹John Hopkins University School of Medicine, Baltimore, MD, ¹⁰Medicine, Medicine, Kingston, Jamaica, ¹¹Microbiology, University of the West Indies, Kgn 7, Jamaica, ¹²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ¹³Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁴Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁵Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Rheumatolgoy/Dept Int Med, Univ of TX Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by recurrent thrombotic and obstetric manifestations in the presence of ‘criteria' antiphospholipid antibodies (aPL) [anticardiolipin (aCL), anti-β2glycoproteinI (anti-β2GPI )…
Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…
Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Laura Andreoli¹, Alessandra Zanola¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²9900 Old Grove road, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…
Abstract Number: 3 • 2014 ACR/ARHP Annual Meeting
Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients?
Doruk Erkan¹, Lisa G. Criscione-Schreiber², Maria Dall'era³, Olga Dvorkina⁴, Russell Griffin⁵, Galina Marder⁶, Maureen A. McMahon⁷, Jorge Sanchez-Guerrero⁸, Amit Saxena⁹ and Robert Roubey¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dept of Med/Rheum Div, Duke University School of Medicine, Durham, NC, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, North Shore Long Island Health System, Great Neck, NY, ⁷Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁸UHN Toronto Western Hospital, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ¹⁰Division of Rheumatology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Few studies assessed the impact of antiphospholipid antibodies (aPL) on organ damage in lupus with conflicting results. Our objective was to determine if persistently…
Abstract Number: 2 • 2014 ACR/ARHP Annual Meeting
Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Ikuma Nakagawa¹, Kenji Oku², Olga Amengual¹, Ryo Hisada¹, Eri Sugawara¹, Kazumasa Ohmura¹, Tomoko Fukui¹, Sanae Shimamura¹, Haruki Shida¹, Toshiyuki Watanabe¹, Yuka Shimizu¹, Michihito Kono¹, Takashi Kurita¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated syndrome refers to organ dysfunctions developed in the existence of antiphospholipid antibodies (aPL), apart from the typical manifestations of antiphospholipid syndrome (APS) such…
Abstract Number: 16 • 2014 ACR/ARHP Annual Meeting
Differential Assay Reactivity of IgA Anti-B₂glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing
David B Hood¹, Karin R Snyder², Tammy R Buckner¹, Beth L Hurley¹, Kelly R Pitts¹ and Luis R Lopez³, ¹R&D, Corgenix, Inc., Broomfield, CO, ²Corgenix, Inc., Broomfield, CO, ³Medical Department, Corgenix, Inc., Broomfield, CO
Background/Purpose: IgA anti-β2Glycoprotein I (aβ2GPI) antibodies remain controversial in the assessment of thrombotic risk in spite of several studies indicating an association with thromboembolic…
Abstract Number: 11 • 2014 ACR/ARHP Annual Meeting
Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome
Alonso Turrent¹, Gabriela Hernandez-Molina² and Antonio R. Cabral³, ¹Immunology and Rheumatology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose: The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been…
Abstract Number: L7 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome without Anticoagulation: 0utcome of 50 Patients
Cécile Yelnik^1,2, Geoffrey Urbanski^1,3, Hélène Maillard^2,4, Aurélia Lanteri^1,2, Noémie Chanson^1,5, Chloé Stavris^1,3, Sandrine Morell-Dubois^1,3, David Launay^3,6,7, Sylvain Dubucquoi^6,7,8, Eric Hachulla^1,3,6, Pierre-Yves Hatron^1,3 and Marc Lambert^1,2, ¹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ²Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, Lille, France, ⁴Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France, ⁵Hôpital Claude Huriez, Lille, France, ⁶EA 2686, Lille, Lille, France, ⁷Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ⁸Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France
Background/Purpose: Long-term anticoagulation is currently the standard treatment for arterial or venous antiphospholipid syndrome (APS). However, in daily clinical practice, the question of withdrawing anticoagulation…
Abstract Number: L21 • 2014 ACR/ARHP Annual Meeting
Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13
Jürgen Braun¹, Xenofon Baraliakos¹, Alex Kudrin², H. Kim³ and Sang Joon Lee², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²CELLTRION, Inc., Incheon, South Korea, ³CELLTRION, Inc, Incheon, Republic of Korea, Incheon, South Korea
Background/Purpose: The differences between RA and AS have been recently highlighted (1). There is evidence that there are major clinical, pathophysiological and genetic differences. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].